key: cord-0995664-z15l4pcq
authors: Lagunas‐Rangel, Francisco Alejandro; Chávez‐Valencia, Venice
title: High IL‐6/IFN‐γ ratio could be associated with severe disease in COVID‐19 patients
date: 2020-04-16
journal: J Med Virol
DOI: 10.1002/jmv.25900
sha: f3ec890af7eaa069410740d36764e242c1f4dda9
doc_id: 995664
cord_uid: z15l4pcq

Cytokines are important mediators of the inflammatory response, and during infection with SARS‐CoV‐2 it has been suggested that there is a cytokine storm syndrome. In this study, a meta‐analysis was performed to investigate whether the IL‐6/IFN‐γ ratio can help predict clinical severity in patients with COVID‐19. This article is protected by copyright. All rights reserved.

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and currently considered by the World Health Organization (WHO) to be a pandemic with more than one million of confirmed cases and almost 57,000 deaths worldwide. 1, 2 Cytokines are important mediators of the inflammatory response. While some cytokines promote inflammation such as IL-6, IL-8, TNF-α, IL-1, IFN-γ and TGF-β, others such as IL-4 and IL-10 have an anti-inflammatory effect. It has been suggested that patients with severe COVID-19, resembling SARS and MERS patients, may have a cytokine storm syndrome characterized by an increase in IL-2, IL-7, G-CSF, CXCL10, MCP-1, MIP-1α, TNF-α and IL-6, suggesting that mortality could be due to viral hyperinflammation that exacerbates lung damage. 3 In this study, a meta-analysis was performed to investigate whether IL-6/IFN-γ ratio can help predict clinical severity in patients with COVID-19.

We conducted an electronic search in different search engines that included Medline (PubMed interface), Scopus and Google Scholar, using the keywords "INF-gamma + COVID-19" OR "IL-6 + COVID-19" OR "Severe 2019-nCoV" OR "Severe COVID-19" without date (until April 5, 2020) or language restrictions. The title, abstract and full text of all the articles identified according to these search criteria were analyzed, considering for our meta-analysis only those that reported data from both parameters, IL-6 and IFN-γ, in COVID-19 patients with or without severe disease.

Only three studies were considered for our analysis. [4] [5] [6] The mean and standard deviation were calculated from the median, range, and sample size as previously described 7 . For all studies, cytokines were measured using cytometric bead arrays and the units used for both parameters were pg/mL. Meta-analysis was performed using Comprehensive Meta-Analysis Software version 3 (Biostat, Englewood, NJ 2013) calculating the standardized mean difference (SMD) and the 95% confidence interval (95% CI) of IL-6/INF-γ ratio in COVID-19 patients with or without severe disease.

All studies were carried out in Chinese hospital centers and included a total number of 

The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 early warning score: a multiparameter screening tool to identify highly suspected patients

Potential Factors for Prediction of Disease Severity of COVID-19 Patients

Immune phenotyping based on neutrophil-tolymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19

Estimating the mean and variance from the median, range, and the size of a sample

Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease